Skip to main content
Top
Published in: Cancer Cell International 1/2020

Open Access 01-12-2020 | Metastasis | Primary research

ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21

Authors: Yuqi Xiang, Liyu Liu, Ying Wang, Bo Li, Jinwu Peng, Deyun Feng

Published in: Cancer Cell International | Issue 1/2020

Login to get access

Abstract

Background

The upregulation of ADAM17 has been reported to be associated with invasion and metastasis in various tumors, however the molecular mechanism of ADAM17 in the progression of hepatocellular carcinoma (HCC) remain to be clarified. Human matrix metalloproteinase 21 (MMP21), the newest member of the MMP gene family, has been suggested to play an important role in embryogenesis and tumor progression. So far, nothing is known about the relationship between ADAM17 and MMP21.

Methods

In this study, the expression level of ADAM17 and MMP21 in HCC tissues was measured by immunohistochemistry. The Scratch wounding assay and Transwell were used to identify the invasion and metastasis ability. ELISA was used to evaluate the production of MMP21. Coimmunoprecipitation experiments demonstrated a direct association between ADAM17 and MMP21. HPLC was used to confirmed that ADAM17 participated in the maturation of MMP21.

Results

Our present data indicated that ADAM17 and MMP21 was significantly upregulated in human HCC tissues. Knockdown of ADAM17 in HCC inhibited cell invasion and metastasis. Moreover, ADAM17 regulates the secretion and expression of MMP21. Furthermore we discovered a direct association between ADAM17 and MMP21, and we also found MMP21 prodomain could be cleaved by ADAM17.

Conclusion

Our data suggest that ADAM17 plays an important role in the development of HCC invasion and metastasis and this function may be implement by MMP21.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;10(401):63–71.CrossRef Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X, He J. Cancer incidence and mortality in China, 2013. Cancer Lett. 2017;10(401):63–71.CrossRef
2.
go back to reference Yang Hao, Fang Feng, Chang Ruimin, Yang Lianyue. MicroRNA-140-5p Suppresses Tumor Growth and Metastasis by Targeting Transforming Growth Factor b Receptor 1 and Fibroblast Growth Factor 9 in Hepatocellular Carcinoma. Hepatology. 2013;58:205–17.CrossRef Yang Hao, Fang Feng, Chang Ruimin, Yang Lianyue. MicroRNA-140-5p Suppresses Tumor Growth and Metastasis by Targeting Transforming Growth Factor b Receptor 1 and Fibroblast Growth Factor 9 in Hepatocellular Carcinoma. Hepatology. 2013;58:205–17.CrossRef
3.
go back to reference Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729–33.CrossRef Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997;385(6618):729–33.CrossRef
4.
go back to reference Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319–35.CrossRef Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319–35.CrossRef
5.
go back to reference Sun J, Jiang J, Lu K, Chen Q, Tao D, Chen Z. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways. Mol Cell Biochem. 2017;426(1–2):17–26.CrossRef Sun J, Jiang J, Lu K, Chen Q, Tao D, Chen Z. Therapeutic potential of ADAM17 modulation in gastric cancer through regulation of the EGFR and TNF-α signalling pathways. Mol Cell Biochem. 2017;426(1–2):17–26.CrossRef
6.
go back to reference Liu HB, Zhu Y, Yang QC, Shen Y, Zhang XJ, Chen H. Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet Mol Res. 2015;14(2):4391–8.CrossRef Liu HB, Zhu Y, Yang QC, Shen Y, Zhang XJ, Chen H. Expression and clinical significance of ADAM17 protein in esophageal squamous cell carcinoma. Genet Mol Res. 2015;14(2):4391–8.CrossRef
7.
go back to reference Zhang C, Han X, Xu X, Zhou Z, Chen X, Tang Y, Cheng J, Moazzam NF, Liu F, Xu J, Peng W, Du F, Zhang B, Song Z, Zeng J, Gong A. FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death Dis. 2018;9(5):469.CrossRef Zhang C, Han X, Xu X, Zhou Z, Chen X, Tang Y, Cheng J, Moazzam NF, Liu F, Xu J, Peng W, Du F, Zhang B, Song Z, Zeng J, Gong A. FoxM1 drives ADAM17/EGFR activation loop to promote mesenchymal transition in glioblastoma. Cell Death Dis. 2018;9(5):469.CrossRef
8.
go back to reference Hu B, Meng X, Zhang Y, Hossain MM, Wu L, Zhang Y, Peng X, Zhang X. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF-7 cells in vitro and in vivo and its mechanism of action. Oncol Rep. 2018;39(4):1640–8.PubMedPubMedCentral Hu B, Meng X, Zhang Y, Hossain MM, Wu L, Zhang Y, Peng X, Zhang X. Short hairpin RNA-mediated gene silencing of ADAM17 inhibits the growth of breast cancer MCF-7 cells in vitro and in vivo and its mechanism of action. Oncol Rep. 2018;39(4):1640–8.PubMedPubMedCentral
9.
go back to reference Wang HP, Wang X, Gong LF, Chen WJ, Hao Z, Feng SW, Wu YB, Ye T, Cai YK. Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway. Eur Rev Med Pharmacol Sci. 2016;20(21):4474–81.PubMed Wang HP, Wang X, Gong LF, Chen WJ, Hao Z, Feng SW, Wu YB, Ye T, Cai YK. Nox1 promotes colon cancer cell metastasis via activation of the ADAM17 pathway. Eur Rev Med Pharmacol Sci. 2016;20(21):4474–81.PubMed
10.
go back to reference . K A, et al, Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Laboratory investigation; a journal of technical methods and pathology. 2003. 83(12): 1887-99. . K A, et al, Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Laboratory investigation; a journal of technical methods and pathology. 2003. 83(12): 1887-99.
11.
go back to reference Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen Z, He Q, Feng D. Micro RNA- 145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep. 2014;32(5):1923–30.CrossRef Liu Y, Wu C, Wang Y, Wen S, Wang J, Chen Z, He Q, Feng D. Micro RNA- 145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma. Oncol Rep. 2014;32(5):1923–30.CrossRef
12.
go back to reference Marchenko GN, Marchenko ND, Strongin AY. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J. 2003;372:503–15.CrossRef Marchenko GN, Marchenko ND, Strongin AY. The structure and regulation of the human and mouse matrix metalloproteinase-21 gene and protein. Biochem J. 2003;372:503–15.CrossRef
13.
go back to reference Ahokas K, Lohi J, Illman SA, Llano E, Elomaa O, Impola U, Karjalainen-Lindsberg ML, Saarialho-Kere U. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest. 2003;83(12):1887–99.CrossRef Ahokas K, Lohi J, Illman SA, Llano E, Elomaa O, Impola U, Karjalainen-Lindsberg ML, Saarialho-Kere U. Matrix metalloproteinase-21 is expressed epithelially during development and in cancer and is up-regulated by transforming growth factor-beta1 in keratinocytes. Lab Invest. 2003;83(12):1887–99.CrossRef
14.
go back to reference Wu T, Li Y, Lu J, Qiao Q, Bao G, Wang N, He X, Du X. Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. Med Oncol. 2013;30(1):323.CrossRef Wu T, Li Y, Lu J, Qiao Q, Bao G, Wang N, He X, Du X. Increased MMP-21 expression is associated with poor overall survival of patients with gastric cancer. Med Oncol. 2013;30(1):323.CrossRef
15.
go back to reference Pu Y, Wang L, Wu H, Feng Z, Wang Y, Guo C. High MMP-21 expression in metastatic lymph nodes predicts unfavorable overall survival for oral squamous cell carcinoma patients with lymphatic metastasis. Oncol Rep. 2014;31(6):2644–50.CrossRef Pu Y, Wang L, Wu H, Feng Z, Wang Y, Guo C. High MMP-21 expression in metastatic lymph nodes predicts unfavorable overall survival for oral squamous cell carcinoma patients with lymphatic metastasis. Oncol Rep. 2014;31(6):2644–50.CrossRef
16.
go back to reference Shu-liang Zhang, Ling Liu. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. EXPERIMENTAL AND THERAPEUTIC MEDICINE. 2015;9(2):579–84.CrossRef Shu-liang Zhang, Ling Liu. microRNA-148a inhibits hepatocellular carcinoma cell invasion by targeting sphingosine-1-phosphate receptor 1. EXPERIMENTAL AND THERAPEUTIC MEDICINE. 2015;9(2):579–84.CrossRef
17.
go back to reference Xu J, Li X, Yang H, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition. Cancer. 2013;119(12):2247–57.CrossRef Xu J, Li X, Yang H, Chang R, Kong C, Yang L. SIN1 promotes invasion and metastasis of hepatocellular carcinoma by facilitating epithelial-mesenchymal transition. Cancer. 2013;119(12):2247–57.CrossRef
18.
go back to reference Feng Fang, Ruimin Chang, Lianyue Yang. Heat Shock Factor 1 Promotes Invasion and Metastasis of Hepatocellular Carcinoma In vitro and In Vivo. Cancer. 2012;118(7):1782–94.CrossRef Feng Fang, Ruimin Chang, Lianyue Yang. Heat Shock Factor 1 Promotes Invasion and Metastasis of Hepatocellular Carcinoma In vitro and In Vivo. Cancer. 2012;118(7):1782–94.CrossRef
19.
go back to reference Zhao Z, Yan L, Li S, Sun H, Zhou Y, Li X. Increased MMP-21 expression in esophageal squamous cell carcinoma is associated with progression and prognosis. Med Oncol. 2014;31(8):91.CrossRef Zhao Z, Yan L, Li S, Sun H, Zhou Y, Li X. Increased MMP-21 expression in esophageal squamous cell carcinoma is associated with progression and prognosis. Med Oncol. 2014;31(8):91.CrossRef
20.
go back to reference Pan Q, Yan W, Wang Y, He X, Zhao Z. Overexpression of MMP21 and MMP28 is associated with gastric cancer progression and poor prognosis. Oncology letters. 2018;15(5):7776–82.PubMedPubMedCentral Pan Q, Yan W, Wang Y, He X, Zhao Z. Overexpression of MMP21 and MMP28 is associated with gastric cancer progression and poor prognosis. Oncology letters. 2018;15(5):7776–82.PubMedPubMedCentral
21.
go back to reference Sung WH, Wonhee H, Jung EC, Jung-Hee K, Daehee H, Seung KY. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget. 2016;7(17):23482–97.CrossRef Sung WH, Wonhee H, Jung EC, Jung-Hee K, Daehee H, Seung KY. Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation. Oncotarget. 2016;7(17):23482–97.CrossRef
22.
go back to reference Li Y, Ren Z, Wang Y, Jung-Hee K, Daehee H, Seung KY. ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma. Exp Cell Res. 2018;370(2):373–82.CrossRef Li Y, Ren Z, Wang Y, Jung-Hee K, Daehee H, Seung KY. ADAM17 promotes cell migration and invasion through the integrin β1 pathway in hepatocellular carcinoma. Exp Cell Res. 2018;370(2):373–82.CrossRef
23.
go back to reference Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385(6618):733–6.CrossRef Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997;385(6618):733–6.CrossRef
24.
go back to reference Caescu CI, Jeschke GR, Turk BE. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J. 2009;424(1):79–88.CrossRef Caescu CI, Jeschke GR, Turk BE. Active-site determinants of substrate recognition by the metalloproteinases TACE and ADAM10. Biochem J. 2009;424(1):79–88.CrossRef
25.
go back to reference Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, Pietrzik C, Becker-Pauly C, Tholey A. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J Proteome Res. 2014;13(4):2205–14.CrossRef Tucher J, Linke D, Koudelka T, Cassidy L, Tredup C, Wichert R, Pietrzik C, Becker-Pauly C, Tholey A. LC-MS based cleavage site profiling of the proteases ADAM10 and ADAM17 using proteome-derived peptide libraries. J Proteome Res. 2014;13(4):2205–14.CrossRef
26.
go back to reference Huang Y, Li W, Chu D, Zheng J, Ji G, Li M, Zhang H, Wang W, Du J, Li J. Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer. J Gastrointest Surg. 2011;15(7):1188–94.CrossRef Huang Y, Li W, Chu D, Zheng J, Ji G, Li M, Zhang H, Wang W, Du J, Li J. Overexpression of matrix metalloproteinase-21 is associated with poor overall survival of patients with colorectal cancer. J Gastrointest Surg. 2011;15(7):1188–94.CrossRef
Metadata
Title
ADAM17 promotes the invasion of hepatocellular carcinoma via upregulation MMP21
Authors
Yuqi Xiang
Liyu Liu
Ying Wang
Bo Li
Jinwu Peng
Deyun Feng
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-020-01556-6

Other articles of this Issue 1/2020

Cancer Cell International 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine